Abstract：Elderly patients are the main group for non-small cell lung cancer (NSCLC). Due to the increased age, the multi-organ reserve of elderly patients decrease, the incidence of comorbidities is higher, resulting in lower tolerance than younger patients, and the choice of treatment options is limited. Therefore, the effective assessment of the physical condition of elderly patients with advanced NSCLC and the choice of treatment options have become the current challenges and the focus of attention. Systemic treatment of elderly patients, such as chemotherapy, targeted therapy and immunotherapy for advanced NSCLC, has been gradually studied and made breakthrough progress. Overall, for chemotherapy, a number of clinical trials conducted in the elderly have shown satisfactory results with platinum-based combination therapy; for anti-angiogenic agents, there is currently insufficient evidence to show the safe use in elderly patients; TKI drugs show good response and tolerability in elderly patients with specific driver mutations, but specific driven gene mutations occur less frequently in older patients; immune checkpoint inhibitors, the strategy of which is to improve the immune status of cancer patients, also achieves effect in elderly patients to a certain extent, so age should not be the only factor to measure whether to receive immunotherapy. This paper reviews the latest research progress and related guidelines for systemic treatment of the elderly population, and hopes to provide a reference for guiding the choice of treatment options for elderly patients.
白日兰，崔久嵬. 老年人晚期非小细胞肺癌系统性治疗的研究进展[J]. 肿瘤代谢与营养电子杂志, 2019, 6(1): 125-134.
BAI Ri-lan, CUI Jiu-wei. Clinical research progress of the systematic treatment for advanced non-small cell lung cancer in the elderly. Electron J Metab Nutr Cancer, 2019, 6(1): 125-134.
2019, Vol. 6 
